Genital Neoplasms clinical trials at UCSF
3 in progress, 2 open to eligible people
Genital neoplasms are tumors that start in the reproductive system. UCSF is studying frailty in patients to measure function and recovery after care. Another UCSF study is testing relacorilant with different treatment regimens to evaluate safety.
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
open to eligible females ages 18 years and up
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
San Francisco, California and other locations
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
open to eligible females ages 18 years and up
This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.
San Francisco, California and other locations
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Sorry, in progress, not accepting new patients
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.
San Francisco, California and other locations
Our lead scientists for Genital Neoplasms research studies include Stephanie Cham, MD.
Last updated: